Stock Performance and Market Context
On 21 August 2026, Parmax Pharma Ltd’s stock price closed at Rs.129.90, setting a fresh 52-week and all-time high. The stock opened and traded steadily at this peak price throughout the day, registering a daily gain of 1.96%, which notably outpaced the Sensex’s modest 0.12% increase. This marks the culmination of a sustained upward trajectory, with the stock having gained for 13 consecutive trading sessions, delivering a cumulative return of 29.06% during this period.
Over longer time horizons, Parmax Pharma’s performance has been exceptional relative to the Sensex benchmark. The stock has surged 10.32% over the past week compared to the Sensex’s decline of 0.49%, and over the past month, it has soared 23.75% against the Sensex’s marginal 0.20% gain. The three-month return stands at an impressive 282.06%, dwarfing the Sensex’s 3.25% rise. Year-to-date, the stock has appreciated by 283.98%, while the Sensex has declined by 8.91%. Even over a five-year span, Parmax Pharma has delivered a 243.65% return, significantly outperforming the Sensex’s 40.30% gain.
Technical Indicators Confirm Bullish Momentum
The technical outlook for Parmax Pharma remains strongly bullish. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling robust upward momentum. The overall technical trend shifted to bullish on 7 August 2026 at a price level of Rs.106.75, and has maintained this positive stance since.
Key technical indicators reinforce this trend: the Moving Average Convergence Divergence (MACD), Bollinger Bands, Know Sure Thing (KST), and Dow Theory readings are all bullish on both weekly and monthly timeframes. Although the Relative Strength Index (RSI) shows a bearish signal on the monthly chart, the broader technical consensus favours continued strength. Immediate support is established at the 52-week low of Rs.22.60, while the stock has decisively surpassed previous resistance levels at Rs.48.32 (200 DMA), Rs.64.10 (100 DMA), and Rs.110.70 (20 DMA).
Valuation and Financial Metrics
Despite the strong price performance, Parmax Pharma remains a micro-cap company with a Mojo Score of 46.0 and a current Mojo Grade of Sell, upgraded from Strong Sell on 10 August 2026. The valuation multiples reflect the company’s loss-making status, with price-to-book value at -7.75x and EV/EBITDA at -23.41x. The EV/Sales multiple stands at 3.18x, while EV/Capital Employed is 12.40x. The company does not currently pay dividends, and dividend yield metrics are not applicable.
The stock’s 52-week range is wide, with a low of Rs.22.60 and the new high of Rs.129.90, representing a substantial 474.78% increase from the low point. This wide range highlights the stock’s volatility and the scale of its recent appreciation.
Quality and Financial Trends
Parmax Pharma’s overall quality grade is below average, reflecting challenges in long-term financial performance. The company has experienced a 5-year sales decline of 6.45% and a significant 213.12% decrease in EBIT over the same period. Average return on capital employed (ROCE) is negative at -28.89%, while return on equity (ROE) is modest at 5.12%. The company benefits from a net cash position, with negative net debt to equity of -1.77, and carries no promoter share pledging.
Short-term financial trends, however, have shown positive momentum. Net sales for the latest six months have grown by 70.31% to ₹11.53 crores. Quarterly profit before depreciation, interest, and tax (Pbdit) reached a high of ₹0.83 crores, with profit before tax less other income at ₹0.12 crores. The company reported its highest quarterly profit after tax (PAT) of ₹2.20 crores and an earnings per share (EPS) of ₹5.88. Delivery volumes have surged, with a 1-month delivery volume increase of 118.37% and a remarkable 726.89% rise in 1-day delivery volume compared to the 5-day average, indicating strong trading interest.
Sector and Market Outperformance
Operating within the Pharmaceuticals & Biotechnology sector, Parmax Pharma has outperformed its sector peers by 2.32% on the day of the new high. Its sustained gains and technical strength stand out in a sector that has seen more modest movements. The stock’s ability to maintain levels above all major moving averages and its consistent upward trend over multiple timeframes underscore its current market leadership within its segment.
Summary of Key Metrics at All-Time High
As of 21 August 2026, Parmax Pharma Ltd’s stock price of Rs.129.90 represents a landmark achievement. The stock’s 13-day consecutive gain of 29.06%, combined with year-to-date returns of 283.98%, highlights a period of exceptional performance. Technical indicators confirm a bullish trend, supported by strong delivery volumes and positive short-term financial results. While valuation multiples and quality grades reflect areas for improvement, the stock’s price action and market behaviour demonstrate a significant milestone in its trading history.
